Impact of cetuximab in current treatment of metastatic colorectal cancer

Bibliography

• Sunada H, Magun BE, Mendelsohn J, MacLeod CL. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA 1986;83:3825-9
   PubMed Web of Science ®Google Scholar
• Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7:301-11
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Santini D, Tonini G. New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor. J Clin Oncol 2006;24:1957
   PubMed Web of Science ®Google Scholar
• Jean GW, Shah SR. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy 2008;28:742-54
   PubMed Web of Science ®Google Scholar
• Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999;5:257-65
   PubMed Web of Science ®Google Scholar
• Fan Z, Masui H, Altas I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1993;53:4322-8
   PubMed Web of Science ®Google Scholar
• Kurai J, Chikumi H, Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007;13:1552-61
   PubMed Web of Science ®Google Scholar
• Martín-Martorell P, Roselló S, Rodríguez-Braun E, et al. Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br J Cancer 2008;99:455-8
   PubMed Web of Science ®Google Scholar
• Pfeiffer P, Nielsen D, Bjerregaard J, et al. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 2008;19:1141-5
   PubMed Web of Science ®Google Scholar
• Mrabti H, la Fouchardiere De C, Desseigne F, et al. Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer. J Cancer Res Ther 2009;5:272-6
   PubMed Web of Science ®Google Scholar
• Bouchahda M, Macarulla T, LIedo G, et al. Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. Med Oncol 2011;28 Suppl 1:S253-8
   PubMed Web of Science ®Google Scholar
• Shitara K, Yuki S, Yoshida M, et al. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Invest New Drugs 2012;30:787-93
   PubMed Web of Science ®Google Scholar
• Kang MJ, Hong YS, Kim K-P, et al. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and wild-type KRAS metastatic colorectal cancer according to epidermal growth factor receptor expression status. Invest New Drugs 2012;30:1607-13
   PubMed Web of Science ®Google Scholar
• Brodowicz T, Ciuleanu TE, Radosavljevic D, et al. FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with wild-type KRAS metastatic colorectal cancer: a randomized phase II CECOG study. Ann Oncol 2013;24:1769-77
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65
   PubMed Web of Science ®Google Scholar
• Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Köhne C-H, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Köhne C-H, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumour KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-19
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011;22:1535-46
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Van Cutsem E, Rougier P, et al. Addition of cetuximab to chemotherapy as first-line treatment for wild-type KRAS metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012;48:1466-75
   PubMed Web of Science ®Google Scholar
• Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:2103-14
   PubMed Web of Science ®Google Scholar
• De Roock W, De Vriendt V, Normanno N, et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011;12:594-603
   PubMed Web of Science ®Google Scholar
• Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010;11:38-47
   PubMed Web of Science ®Google Scholar
• Ye L-C, Liu T-S, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with wild-type KRAS unresectable colorectal liver-limited metastases. J Clin Oncol 2013;31:1931-8
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-7
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34
   PubMed Web of Science ®Google Scholar
• De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62
   PubMed Web of Science ®Google Scholar
• Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007;96:1166-9
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
   PubMed Web of Science ®Google Scholar
• Lea IA, Jackson MA, Li X, et al. Genetic pathways and mutation profiles of human cancers: site-and exposure-specific patterns. Carcinogenesis 2007;28:1851-8
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8
   PubMed Web of Science ®Google Scholar
• Normanno N, Tejpar S, Morgillo F, et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009;6:519-27
   PubMed Web of Science ®Google Scholar
• Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-72
   PubMed Web of Science ®Google Scholar
• Bazan V, Migliavacca M, Zanna I, et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 2002;13:1438-46
   PubMed Web of Science ®Google Scholar
• Lièvre A, Bachet J-B, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5
   PubMed Web of Science ®Google Scholar
• Custodio A, Feliu J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Crit Rev Oncol Hematol 2013;85:45-81
   PubMed Web of Science ®Google Scholar
• Troiani T, Zappavigna S, Martinelli E, et al. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Expert Opin Biol Ther 2013;13:241-55
   PubMed Web of Science ®Google Scholar
• Moosmann N, Weikersthal von LF, Vehling-Kaiser U, et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104–a randomized trial of the German AIO CRC study group. J Clin Oncol 2011;29:1050-8
   PubMed Web of Science ®Google Scholar
• Vecchione L, Jacobs B, Normanno N, et al. EGFR-targeted therapy. Exp Cell Res 2011;317:2765-71
   PubMed Web of Science ®Google Scholar
• Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063-9
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12
   PubMed Web of Science ®Google Scholar
• Zlobec I, Bihl MP, Schwarb H, et al. Clinicopathological and protein characterization of BRAF-and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer 2010;127:367-80
   PubMed Web of Science ®Google Scholar
• Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934
   PubMed Web of Science ®Google Scholar
• Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signalling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643-8
   PubMed Web of Science ®Google Scholar
• Tol J, Nagtegaal ID, Punt CJA. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009;361:98-9
   PubMed Web of Science ®Google Scholar
• Tol J, Dijkstra JR, Klomp M, et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010;46:1997-2009
   PubMed Web of Science ®Google Scholar
• Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009;27:5931-7
   PubMed Web of Science ®Google Scholar
• Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-6
   PubMed Web of Science ®Google Scholar
• Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009;101:715-21
   PubMed Web of Science ®Google Scholar
• Oliner KS, Douillard J-Y, Siena S, et al. Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). J Clin Oncol 2013;31(Suppl 15):abstract 3511
   Google Scholar
• Haigis KM, Kendall KR, Wang Y, et al.Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumour progression in the colon. Nat Genet 2008;40:600-8
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK (study 20070509): a randomized phase II study of mFOLFOX6 with either panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) in patients (pts) with unresectable wild-type (WT) KRAS metastatic colorectal cancer (mCRC). J Clin Oncol 2013;31(Suppl 4):abstract 446
   Google Scholar
• Schwartzberg LS, Rivera F, Karthaus M, et al. Analysis of KRAS/NRAS mutations in PEAK: a randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC). J Clin Oncol 2013;31(Suppl 15):abstract 3631
   Google Scholar
• Douillard J-Y, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-34
   PubMed Web of Science ®Google Scholar
• Stintzing S, Jung A, Rossius L, et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients [abstract 17]. European Cancer Congress ESMO 2013
   Google Scholar
• Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009;4:e7287
   PubMed Web of Science ®Google Scholar
• Jacobs B, De Roock W, Piessevaux H, et al. Amphiregulin and epiregulin mRNA expression in primary tumours predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009;27:5068-74
   PubMed Web of Science ®Google Scholar
• Souglakos J, Philips J, Wang R, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009;101:465-72
   PubMed Web of Science ®Google Scholar
• Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumours and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009;27:2622-9
   PubMed Web of Science ®Google Scholar
• Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009;27:5924-30
   PubMed Web of Science ®Google Scholar
• Tabernero J, Cervantes A, Rivera F, et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010;28:1181-9
   PubMed Web of Science ®Google Scholar
• Baker JB, Dutta D, Watson D, et al. Tumour gene expression predicts response to cetuximab in patients with wild-type KRAS metastatic colorectal cancer. Br J Cancer 2011;104:488-95
   PubMed Web of Science ®Google Scholar
• Di Bartolomeo M, Pietrantonio F, Perrone F, et al. Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. Target Oncol 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Pentheroudakis G, Kotoula V, De Roock W, et al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer 2013;13:49
   PubMed Web of Science ®Google Scholar
• Portier G, Elias D, Bouché O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006;24:4976-82
   PubMed Web of Science ®Google Scholar
• Mitry E, Fields ALA, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008;26:4906-11
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007-16
   PubMed Web of Science ®Google Scholar
• Primrose JN, Falk S, Finch-Jones M, et al. A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: the new EPOC study. J Clin Oncol 2013;31(Suppl 15):abstract 3504
   Google Scholar
• Muratore A, Zorzi D, Bouzari H, et al. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 2007;14:766-70
   PubMed Web of Science ®Google Scholar
• Dexiang Z, Li R, Ye W, et al. Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases. Ann Surg Oncol 2012;19:2860-8
   PubMed Web of Science ®Google Scholar
• Saiura A, Yamamoto J, Hasegawa K, et al. Liver resection for multiple colorectal liver metastases with surgery up-front approach: bi-institutional analysis of 736 consecutive cases. World J Surg 2012;36:2171-8
   PubMed Web of Science ®Google Scholar
• Nanji S, Cleary S, Ryan P, et al. Up-front hepatic resection for metastatic colorectal cancer results in favorable long-term survival. Ann Surg Oncol 2013;20:295-304
   PubMed Web of Science ®Google Scholar
• Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001;8:347-53
   PubMed Web of Science ®Google Scholar
• Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644-57. discussion657–8
   PubMed Web of Science ®Google Scholar
• Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004;15:933-9
   PubMed Web of Science ®Google Scholar
• Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005;23:9243-9
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006;42:2212-21
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Van Cutsem E, Rougier P, et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007;43:2037-45
   PubMed Web of Science ®Google Scholar
• Nuzzo G, Giuliante F, Ardito F, et al. Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg 2007;11:318-24
   PubMed Web of Science ®Google Scholar
• Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009;27:1829-35
   PubMed Web of Science ®Google Scholar
• Folprecht G, Lutz MP, Schöffski P, et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006;17:450-6
   PubMed Web of Science ®Google Scholar
• Raoul J-L, Van Laethem J-L, Peeters M, et al. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer 2009;9:112
   PubMed Web of Science ®Google Scholar
• Arnold D, Hohler T, Dittrich C, et al. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann Oncol 2008;19:1442-9
   PubMed Web of Science ®Google Scholar
• Tabernero J, Van Cutsem E, Diaz-Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007;25:5225-32
   PubMed Web of Science ®Google Scholar
• Folprecht G, Gruenberger T, Bechstein W, et al. Progression free and overall survival after neoadjuvant treatment of colorectal liver metastases with cetuximab plus FOLFOX or FOLFIRI-Results of the CELIM study. Eur J Cancer 2011;47(Suppl 1):S394
   Google Scholar
• Folprecht G, Gruenberger T, Bechstein W, et al. Cetuximab and chemotherapy in the treatment of patients with initially “nonresectable” colorectal (CRC) liver metastases: long-term follow-up of the CELIM trial. J Clin Oncol 2013;31(Suppl 15):abstract 3538
   Google Scholar
• Garufi C, Torsello A, Tumolo S, et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010;103:1542-7
   PubMed Web of Science ®Google Scholar
• Saridaki Z, Androulakis N, Vardakis N, et al. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial. Br J Cancer 2012;107:1932-7
   PubMed Web of Science ®Google Scholar
• Assenat E, Desseigne F, Thezenas S, et al. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist 2011;16:1557-64
   PubMed Web of Science ®Google Scholar
• Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670-6
   PubMed Web of Science ®Google Scholar
• Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012;30:1755-62
   PubMed Web of Science ®Google Scholar
• Broadbridge VT, Karapetis CS, Price TJ. Cetuximab in metastatic colorectal cancer. Expert Rev Anticancer Ther 2012;12:555-65
   PubMed Web of Science ®Google Scholar
• Woo J, Palmisiano N, Tester W, Leighton JC. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer. Cancer 2013;119:1941-50
   PubMed Web of Science ®Google Scholar
• Lindsay CR, Roxburgh P, Graham J. How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer? Future Oncol 2013;9:825-9
   PubMed Web of Science ®Google Scholar
• Ocvirk J, Brodowicz T, Wrba F, et al. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 2010;16:3133-43
   PubMed Web of Science ®Google Scholar
• Stintzing S, Fischer von Weikersthal L, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol 2012;23:1693-9
   PubMed Web of Science ®Google Scholar
• Heinemann V, Weikersthal von LF, Decker T, et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of wild-type KRAS metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). J Clin Oncol 2013;31(Suppl 18):abstract LBA3506
   Google Scholar
• Mansmann UR, Sartorius U, Laubender RP, et al. Quantitative analysis of the impact of deepness of response on postprogression survival time following first-line treatment in patients with mCRC. J Clin Oncol 2013;31(Suppl 15):abstract 3630
   Google Scholar
• Mansmann U, Sartorius U, Laubender R, et al. Quantitative analysis of the impact of deepness of response on post-progression survival time following first-line treatment in patients with mCRC. Ann Oncol 2013;24(Suppl 4):iv14-15
   Google Scholar
• Modest D, Weikersthal von LF, Stintzing S, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). Ann Oncol 2013;24(Suppl 4):iv22-3
   Google Scholar
• Piessevaux H, Schlichting M, Heeger S, et al. Early tumour shrinkage for the prediction of efficacy of cetuximab in metastatic colorectal cancer (mCRC): analysis from the CRYSTAL study. Ann Oncol 2010;21(Suppl 8):viii189-224
   Google Scholar
• Piessevaux H, Buyse M, Schlichting M, et al. Use of early tumour shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2013;31:3764-75
   PubMed Web of Science ®Google Scholar
• Modest DP, Laubender RP, Stintzing S, et al. Early tumour shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial. Acta Oncol 2013;52:956-62
   PubMed Web of Science ®Google Scholar
• Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-19
   PubMed Web of Science ®Google Scholar
• Au H-J, Karapetis CS, O'Callaghan CJ, et al. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. J Clin Oncol 2009;27:1822-8
   PubMed Web of Science ®Google Scholar
• Láng I, Köhne C-H, Folprecht G, et al. Quality of life analysis in patients with wild-type KRAS metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. Eur J Cancer 2013;49:439-48
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Wallace JF, Holmgren E, et al. Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. Oncologist 2008;13:1021-9
   PubMed Web of Science ®Google Scholar
• Bennett L, Zhao Z, Barber B, et al. Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first-or second-line treatment. Br J Cancer 2011;105:1495-502
   PubMed Web of Science ®Google Scholar
• Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37
   PubMed Web of Science ®Google Scholar
• Hatanaka K, Yuki S, Sasaki T, et al. Comparison of cetuximab with panitumumab in salvage-line monotherapy against wild-type KRAS type patients with metastatic colorectal cancer: analysis of HGCSG0901 and HGCSG1002 [abstract2396]. European Cancer Congress ESMO 2013
   Google Scholar